425: Strive and Semler Scientific Advance Merger Plans

Strive, Inc. and Semler Scientific, Inc. are progressing with their proposed business combination, as detailed in recent SEC filings and communications.

Summary

• Strive, Inc. and Semler Scientific, Inc. are moving forward with a proposed business combination.
• The communication regarding the proposed transaction was reposted on X.com by Matthew Cole, CEO of Strive, Inc., on December 11, 2025.
• Strive has filed a Registration Statement on Form S-4 with the SEC, which includes an Information Statement/Proxy Statement/Prospectus.
• The definitive Information Statement/Proxy Statement/Prospectus will be sent to Semler Scientific stockholders to seek their approval of the proposed transaction.
• The filing includes extensive cautionary statements regarding forward-looking statements and inherent risks and uncertainties associated with the transaction.

Sentiment

Score: 5

Explanation: The filing is a standard pre-merger communication, outlining the proposed transaction and extensively detailing associated risks and forward-looking statement disclaimers. It does not provide new positive or negative operational results, maintaining a neutral stance.

Positives

• The proposed transaction is expected to yield strategic benefits for the combined company.
• Anticipated financial benefits include a positive impact on the combined company's future financial performance.
• The business combination is expected to result in anticipated cost savings and strategic gains.

Risks

• The merger agreement could be terminated by either Strive or Semler Scientific due to various circumstances.
• The proposed transaction may not close as expected or at all if closing conditions are not met or satisfied timely.
• Legal proceedings may be instituted against Strive, Semler Scientific, or the combined company, impacting the transaction.
• Anticipated benefits, including cost savings and strategic gains, may not be realized due to changes in Bitcoin treasury strategies, digital asset risks, economic conditions, or regulatory factors.
• The integration of the two companies could be more difficult, time-consuming, or costly than anticipated.
• The proposed transaction may be more expensive or take longer to complete than expected due to unforeseen factors.
• Management's attention may be diverted from ongoing business operations and opportunities during the transaction process.
• Strive's issuance of additional shares of Class A common stock in connection with the transaction will cause dilution.
• There is a risk of adverse reactions from Strive's or Semler Scientific's customers or changes to business or employee relationships.
• Changes in Strive's or Semler Scientific's share price before closing could negatively impact the transaction.
• Other unknown or unpredictable factors could harm the results of Strive, Semler Scientific, or the combined company.

Future Outlook

The companies anticipate strategic and financial benefits from the proposed transaction, including improved future financial performance and potential cost savings, though these are subject to significant risks and uncertainties related to integration, market conditions, and regulatory factors.

Management Comments

• Strive's Chief Executive Officer, Matthew Cole, reposted the communication on X.com regarding the proposed business combination with Semler Scientific.

Industry Context

The mention of 'Bitcoin treasury strategies and risks associated with Bitcoin and other digital assets' suggests that the combined entity may be pursuing or expanding into digital asset management, a notable trend for some companies seeking diversification or alternative treasury strategies, potentially shifting the strategic focus for Semler Scientific, traditionally a medical device company.

Corporate Governance

Legal Proceedings

• Potential legal proceedings may be instituted against Strive, Semler Scientific, or the combined company in connection with the proposed transaction.

Stakeholder Impact

• Shareholders: Potential dilution for Strive shareholders, requirement for Semler Scientific shareholders to vote on the transaction, and potential changes in share price for both companies.
• Customers: Potential for adverse reactions or changes to business relationships for both Strive and Semler Scientific.
• Employees: Potential for changes to employee relationships for both Strive and Semler Scientific.

Next Steps

• A definitive Information Statement/Proxy Statement/Prospectus will be sent to the stockholders of Semler Scientific.
• Semler Scientific stockholders will be asked to approve the proposed transaction.
• Strive and Semler Scientific will continue to file relevant documents with the SEC concerning the proposed transaction.

Key Dates

Recommendation

The filing details a proposed business combination between Strive and Semler Scientific, accompanied by extensive disclosures of forward-looking statements and associated risks. While the merger presents potential strategic and financial benefits, the numerous uncertainties, including integration challenges, market conditions, and potential dilution, suggest a 'hold' recommendation. Investors should await further definitive information, including the full Information Statement/Proxy Statement/Prospectus, and monitor the progress of the transaction and market reactions before making significant investment decisions.

Keywords

Merger, Business Combination, Strive Inc., Semler Scientific Inc., SEC Filing, Form 425, Corporate Governance, Risk Management, Bitcoin Treasury, Digital Assets